Doxorubicin treatment induces tumor cell death followed by immunomodulation in a murine neuroblastoma model
- Authors:
- Published online on: January 17, 2014 https://doi.org/10.3892/etm.2014.1489
- Pages: 703-708
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Chemotherapy of malignant tumors induces tumor cell death. Numerous antitumor agents induce apoptosis of tumor cells, which are subsequently engulfed by phagocytes, initiating an immune reaction. The induction of immunogenic cell death by antitumor agents may be advantageous for antitumor immunity. The purpose of this study was to determine whether doxorubicin is capable of inducing an immunogenic reaction in murine neuroblastoma cells. The murine neuroblastoma cell line (neuro‑2a cells) was cultured in a medium containing doxorubicin or cisplatin (CDDP), and induction of cell death was confirmed by cell viability assays. Cluster of differentiation (CD)8α+ lymphocytes were co‑cultured with neuro‑2a cells that had died following treatment with either doxorubicin or CDDP, and CD11b+ spleen cells or bone marrow‑derived dendritic cells (BM‑DCs) were added to the culture. Proliferation of CD8α+ lymphocytes and interferon (IFN)‑γ production were evaluated. When CD8α+ cells were co‑cultured with doxorubicin‑treated neuro‑2a cells and BM‑DCs, CD8α+ cells reacted to anti‑CD3/CD28 antibody stimulation, proliferated and increased IFN‑γ production. IFN‑γ production was more effectively promoted by co‑culture with doxorubicin‑treated neuro‑2a cells than by co‑culture with CDDP‑treated neuro‑2a cells. These findings suggest that doxorubicin is capable of inducing immunogenic cell death in neuroblastoma cells, and thus has an immunological advantage for chemotherapy of neuroblastoma compared with CDDP. BM‑DCs are considered to be the key antigen‑presenting cells in the immune reaction following the induction of immunogenic neuroblastoma cell death and phagocytosis.
